Rophibio, Inc.
Biotechnology company developing biosimilars and biopharmaceuticals including gene- and cell-based therapies. Maintains candidate pipelines for biosimilars and novel biologics, conducts global clinical development and regulatory submissions for late-stage trials, and performs process development for biologic products. Engages in industry partnerships and has secured external investment.
Industries
N/A
Products
Biosimilar candidate pipeline
Pipeline of biosimilar development programs across multiple therapeutic areas, advanced into late-stage clinical development.
Biopharmaceutical (novel) candidate pipeline
Pipeline of novel biopharmaceuticals including gene- and cell-therapy candidates for therapeutic development.
Biosimilar candidate pipeline
Pipeline of biosimilar development programs across multiple therapeutic areas, advanced into late-stage clinical development.
Biopharmaceutical (novel) candidate pipeline
Pipeline of novel biopharmaceuticals including gene- and cell-therapy candidates for therapeutic development.
Expertise Areas
- Biosimilar development
- Biopharmaceutical R&D (including gene and cell therapies)
- Clinical development and regulatory submissions for late-stage trials
- Process development for biologics (monoclonal antibodies)
Key Technologies
- Biosimilar development
- Gene and cell therapy platforms
- Monoclonal antibody process development
- Clinical IND submission workflows